|1.||van Poelje, Paul D: 2 articles (01/2011 - 06/2006)|
|2.||Erion, Mark D: 2 articles (01/2011 - 06/2006)|
|3.||Potter, Scott C: 2 articles (01/2011 - 06/2006)|
|4.||Okuno, Akira: 1 article (12/2008)|
|5.||Izumi, Masanori: 1 article (12/2008)|
|6.||Takahashi, Kanako: 1 article (12/2008)|
|7.||Ohsumi, Jun: 1 article (12/2008)|
|8.||Fujiwara, Toshihiko: 1 article (12/2008)|
|9.||Hagisawa, Yuka: 1 article (12/2008)|
|10.||Yoshida, Taishi: 1 article (12/2008)|
12/28/2008 - " findings suggest that enhanced gluconeogenesis contributes to hyperglycemia in postprandial conditions as well as in fasting conditions, and that CS-917 as an FBPase inhibitor corrects postprandial hyperglycemia as well as fasting hyperglycemia."
12/28/2008 - "The suppressive effect of CS-917 on postprandial hyperglycemia was evaluated in a meal loading test in Goto-Kakizaki (GK) rats, non-obese type 2 diabetic animal model characterized by impaired insulin secretion. "
12/28/2008 - "CS-917, a fructose 1,6-bisphosphatase inhibitor, improves postprandial hyperglycemia after meal loading in non-obese type 2 diabetic Goto-Kakizaki rats."
06/01/2006 - "In high-fat diet-fed female ZDF rats, MB06322 treatment for 2 weeks fully attenuated hyperglycemia without evidence of metabolic perturbation other than a modest reduction in glycogen stores ( approximately 20%). "
12/28/2008 - "In this study, we evaluated the effect of gluconeogenesis inhibition on postprandial hyperglycemia using CS-917, a novel inhibitor of fructose 1,6-bisphphosphatase (FBPase) which is one of the rate-limiting enzymes of gluconeogenesis. "
|3.||Hypoglycemia (Reactive Hypoglycemia)
|7.||fructose-1,6-diphosphate (fructose 1,6-diphosphate)